血浆代谢谱揭示癌症免疫治疗结局的代谢决定因素
该研究通过靶向代谢组学和宏基因组学分析了5种肿瘤类型、16个队列、1714例患者的4336份血浆样本,构建多模态机器学习模型,识别出5种代谢物、年龄、BMI和肾功能可预测12个月无进展生存期;组氨酸为有利预后特征,长链脂肪酸和琥珀酸与不良结局相关,组氨酸饮食可改善部分患者无进展生存期。
要点
- 血浆代谢谱联合临床变量可预测免疫检查点抑制剂治疗的12个月无进展生存期。
- 组氨酸为有利预后特征,长链脂肪酸和琥珀酸与不良结局相关。
- 组氨酸饮食可改善无组氨酸分解相关菌群失调特征患者的无进展生存期。
核心结论
- 血浆代谢特征与免疫检查点抑制剂治疗结局相关,组氨酸为有利预后特征,长链脂肪酸和琥珀酸与不良结局相关。
研究设计与样本
- 研究采用靶向代谢组学和宏基因组学,对5种肿瘤类型、16个队列的1714例患者共4336份血浆样本进行纵向分析,覆盖欧洲和北美。
- 样本来自接受5种免疫检查点抑制剂为基础的治疗模式(包括粪菌移植)的患者。
主要发现
- 多模态机器学习框架整合154种代谢物与临床变量,识别出5种代谢物、年龄、BMI和肾功能可预测12个月无进展生存期。
- 模型在105例训练队列和30例验证队列中的AUC分别为0.88和0.73,并在7个外部队列中具有泛化性。
- 组氨酸为有利预后特征,长链脂肪酸和琥珀酸与不良结局相关。
- 组氨酸补充可增强小鼠抗肿瘤免疫。
- 组氨酸丰富饮食可改善缺乏组氨酸分解相关菌群失调特征患者的无进展生存期。
临床怎么用
- 血浆代谢谱联合临床变量或可用于免疫检查点抑制剂治疗前的无进展生存期预测。
- 组氨酸丰富饮食可能改善缺乏组氨酸分解相关菌群失调特征患者的无进展生存期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune-checkpoint inhibitors benefit a subset of patients with advanced cancer, and the metabolic determinants of response remain unclear. Here, using targeted metabolomics and metagenomics, we profiled 4,336 plasma samples from 1,714 patients across five tumor types and 16 cohorts spanning Europe and North America, longitudinally sampled during five immune-checkpoint inhibitor-based treatment modalities, including fecal microbiota transplantation. A multimodal machine-learning framework integrating 154 metabolites with clinical variables identified five metabolites, age, body mass index and renal function as predictors of 12-month progression-free survival. The model achieved areas under the curve of 0.88 in training and 0.73 in validation cohorts of 105 and 30 patients, respectively and generalized across seven external cohorts. Histidine was a favorable prognostic feature of survival, whereas long-chain fatty acids and succinate were negatively associated with outcome. Histidine supplementation enhanced antitumor immunity in mice. Histidine-rich diets improved progression-free survival in patients lacking dysbiotic microbiome signatures associated with histidine catabolism.
引用
- Suissa D, Fidelle M, Reich E, et al. Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling. Nat Med. 2026. PMID: 42350644. doi:10.1038/s41591-026-04481-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。